Lipotoxicity and cardiac dysfunction in mammals and Drosophila

Critical Reviews in Biochemistry and Molecular Biology

Volumn 46, Issue 5, 2011, Pages 376-385

  Birse, Ryan Tyge ^a   Bodmer, Rolf ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Heart function; Lipid metabolism; Obesity

Indexed keywords

CERAMIDE; FATTY ACID; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; BIOGENESIS; CARDIOLIPOTOXICITY; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DISEASE SEVERITY; DROSOPHILA; FATTY ACID OXIDATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLUCONEOGENESIS; HEART DISEASE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; MAMMAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; DROSOPHILA; GLUCOSE; HUMANS; INSULIN; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; PHOSPHOLIPIDS;

MAMMALIA;

EID: 80053465191     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2011.599830     Document Type: Review

References (95)

1. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. 2005. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 96:412-418. (Pubitemid 40354534)
2. Baker KD, Tummel CS. 2007. Diabetic larvae and obese fies-emerging studies of metabolism in Drosophila. Cell Metab 6:257-266. (Pubitemid 47450188)
3. Birse RT, Choi J, Reardon K, Rodriguez J, Graham S, Diop S, Ocorr K, Bodmer R, Oldham S. 2010. High-fat-diet-induced obesity and heart dysfunction are regulated by the TOR pathway in Drosophila. Cell Metab 12:533-544.
4. Bodmer R, Venkatesh TV. 1998. Heart development in Drosophila and vertebrates: conservation of molecular mechanisms. Dev Genet 22:181-186. (Pubitemid 28257595)
5. Bouzakri K, Koistinen HA, Zierath JR. 2005. Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes. Curr Diabetes Rev 1:167-174.
6. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR. 2010. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 298:E897-E908.
7. Browning JD, Horton JD. 2004. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152. (Pubitemid 39071617)
8. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. 2004. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-174.
9. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schafer JE. 2005. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96:225-233. (Pubitemid 40209370)
10. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saftz JE, Schafer JE. 2001. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107:813-822. (Pubitemid 32274034)
11. Chow L, From A, Seaquist E. 2010. Skeletal muscle insulin resistance: the interplay of local lipid excess and mitochondrial dysfunction. Metab Clin Exp 59:70-85.
12. Christofersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, Nielsen LB. 2003. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144:3483-3490. (Pubitemid 36904426)
13. Cripps RM, Olson EN. 2002. Control of cardiac development by an evolutionarily conserved transcriptional network. Dev Biol 246:14-28. (Pubitemid 34625972)
14. DeFronzo RA, Tripathy D. 2009. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 Suppl 2:S157-S163.
15. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. 2010. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120:4342-4352.
16. Després JP. 2007. Cardiovascular disease under the infuence of excess visceral fat. Crit Pathw Cardiol 6:51-59.
17. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. 2010. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifes sources of cardiac lipids and peroxisome proliferator- activated receptor-alpha activators. Circulation 121:426-435.
18. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, Donath MY. 2001. Glucose and palmitic acid induce degeneration of myofbrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50:2105-2113. (Pubitemid 33643679)
19. Fabbrini E, Sullivan S, Klein S. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689.
20. Feldstein AE. 2010. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30:391-401.
21. Forouhi NG, Jenkinson G, Tomas EL, Mullick S, Mierisova S, Bhonsle U, McKeigue PM, Bell JD. 1999. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 42:932-935. (Pubitemid 29369600)
22. Fujita M, Momose A, Ohtomo T, Nishinosono A, Tanonaka K, Toyoda H, Morikawa M, Yamada J. 2011. Upregulation of fatty acyl-CoA thioesterases in the heart and skeletal muscle of rats fed a high-fat diet. Biol Pharm Bull 34:87-91.
23. Glenn DJ, Wang F, Nishimoto M, Cruz MC, Uchida Y, Holleran WM, Zhang Y, Yeghiazarians Y, Gardner DG. 2011. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 57:216-222.
24. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305.
25. Goldberg RB. 2009. Cytokine and cytokine-like infammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171-3182.
26. Górska M, Dobrzyn A, Zendzian-Piotrowska M, Górski J. 2004. Efect of streptozotocin-diabetes on the functioning of the sphingomyelin- signalling pathway in skeletal muscles of the rat. Horm Metab Res 36:14-21. (Pubitemid 38283188)
27. Grönke S, Mildner A, Fellert S, Tennagels N, Petry S, Müller G, Jäckle H, Kühnlein RP. 2005. Brummer lipase is an evolutionary conserved fat storage regulator in Drosophila. Cell Metab 1:323-330. (Pubitemid 43960616)
28. Grönke S, Müller G, Hirsch J, Fellert S, Andreou A, Haase T, Jäckle H, Kühnlein RP. 2007. Dual lipolytic control of body fat storage and mobilization in Drosophila. PLoS Biol 5:e137.
29. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Teussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefer G, Zechner R. 2006. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734-737.
30. Hannun YA, Obeid LM. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9:139-150. (Pubitemid 351158911)
31. Heather LC, Clarke K. 2011. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50:598-605.
32. Hickson-Bick DL, Buja LM, McMillin JB. 2000. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32:511-519.
33. Hirano K, Ikeda Y, Zaima N, Sakata Y, Matsumiya G. 2008. Triglyceride deposit cardiomyovasculopathy. N Engl J Med 359:2396-2398.
34. Hoy AJ, Bruce CR, Turpin SM, Morris AJ, Febbraio MA, Watt MJ. 2011. Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation. Endocrinology 152:48-58.
35. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. 2004. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308-10313. (Pubitemid 38924921)
36. Hulver MW, Berggren JR, Cortright RN, Dudek RW, Tompson RP, Pories WJ, MacDonald KG, Cline GW, Shulman GI, Dohm GL, Houmard JA. 2003. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 284:E741-E747. (Pubitemid 36323867)
37. Janero DR, Burghardt B, Lopez R. 1988. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 37:4197-4203.
38. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. 2005. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22:1141-1145. (Pubitemid 41224170)
39. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. 1987. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186.
40. Kim SK, Rulifson EJ. 2004. Conserved mechanisms of glucose sensing and regulation by Drosophila corpora cardiaca cells. Nature 431:316-320. (Pubitemid 39265667)
41. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, Yki-Järvinen H. 2008. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165-169.
42. Laplante M, Sabatini DM. 2009. An emerging role of mTOR in lipid biosynthesis. Curr Biol 19:R1046-R1052.
43. Laplante M, Sabatini DM. 2010. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci USA 107:3281-3282.
44. Li LO, Klett EL, Coleman RA. 2010. Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta 1801:246-251.
45. Lim HY, Wang W, Wessells RJ, Ocorr K, Bodmer R. 2011. Phospholipid homeostasis regulates lipid metabolism and cardiac function through SREBP signaling in Drosophila. Genes Dev 25:189-200.
46. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schafer JE, Yu YH, Goldberg IJ. 2009. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 284:36312-36323.
47. Liu L, Yu S, Khan RS, Ables GP, Bharadwaj KG, Hu Y, Huggins LA, Eriksson JW, Buckett LK, Turnbull AV, Ginsberg HN, Blaner WS, Huang LS, Goldberg IJ. 2011. DGAT1 defciency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res 52:732-744.
48. Löllmann B, Grüninger S, Stricker-Krongrad A, Chiesi M. 1997. Detection and quantifcation of the leptin receptor splice variants Ob-Ra, b, and, e in diferent mouse tissues. Biochem Biophys Res Commun 238:648-652. (Pubitemid 27464444)
49. Lopaschuk GD, Folmes CD, Stanley WC. 2007. Cardiac energy metabolism in obesity. Circ Res 101:335-347. (Pubitemid 47267702)
50. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. 2010. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258.
51. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP. 2008. Visceral obesity and the heart. Int J Biochem Cell Biol 40:821-836.
52. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Tompson SG. 1986. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533-537. (Pubitemid 16054632)
53. Neely GG, Kuba K, Cammarato A, Isobe K, Amann S, Zhang L, Murata M, Elmén L, Gupta V, Arora S, Sarangi R, Dan D, Fujisawa S, Usami T, Xia CP, Keene AC, Alayari NN, Yamakawa H, Elling U, Berger C, Novatchkova M, Koglgruber R, Fukuda K, Nishina H, Isobe M, Pospisilik JA, Imai Y, Pfeufer A, Hicks AA, Pramstaller PP, Subramaniam S, Kimura A, Ocorr K, Bodmer R, Penninger JM. 2010. A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell 141:142-153.
54. Ocorr K, Akasaka T, Bodmer R. 2007. Age-related cardiac disease model of Drosophila. Mech Ageing Dev 128:112-116. (Pubitemid 46075231)
55. Oldham S, Hafen E. 2003. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 13:79-85. (Pubitemid 36135889)
56. Palanker L, Tennessen JM, Lam G, Tummel CS. 2009. Drosophila HNF4 regulates lipid mobilization and beta-oxidation. Cell Metab 9:228-239.
57. Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, Wu JJ, Bennett AM, Rothermel B, Kalinowski A, Russell KS, Kim YB, Kelly DP, Kim JK. 2005. Cardiac-specifc overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes 54:2514-2524. (Pubitemid 41233572)
58. Perseghin G. 2010. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 28:210-213.
59. Peura TT, Bosman A, Stojanov T. 2007. Derivation of human embryonic stem cell lines. Teriogenology 67:32-42. (Pubitemid 44854150)
60. Picano E, Morales MA, del Ry S, Sicari R. 2010. Innate infammation in myocardial perfusion and its implication for heart failure. Ann N Y Acad Sci 1207:107-115.
61. Phillips LK, Prins JB. 2008. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 10:156-164.
62. Puthanveetil P, Wang Y, Zhang D, Wang F, Kim MS, Innis S, Pulinilkunnil T, Abrahani A, Rodrigues B. 2011. Cardiac triglyceride accumulation following acute lipid excess occurs through activation of a FoxO1-iNOS-CD36 pathway. Free Radic Biol Med 51:352-363.
63. Qian L, Liu J, Bodmer R. 2008. Heart development in Drosophila. In Bodmer R, ed. Advances in Developmental Biology: Cardiac Development. Amsterdam, Elsevier, 1-29
64. Rawson RB. 2003. The SREBP pathway-insights from Insigs and insects. Nat Rev Mol Cell Biol 4:631-640.
65. Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806. (Pubitemid 34000783)
66. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfefer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. 2003. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42:1050-1065. (Pubitemid 37413751)
67. Schifrin EL, Lipman ML, Mann JF. 2007. Chronic kidney disease: efects on the cardiovascular system. Circulation 116:85-97. (Pubitemid 47016250)
68. Schrauwen-Hinderling VB, Mensink M, Hesselink MK, Sels JP, Kooi ME, Schrauwen P. 2008. The insulin-sensitizing efect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function. J Clin Endocrinol Metab 93:2917-2921. (Pubitemid 352008572)
69. Sentex E, Sergiel JP, Lucien A, Grynberg A. 1997. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 175:153-162. (Pubitemid 27453349)
70. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. 2004. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18:1692-1700. (Pubitemid 39463708)
71. Stanley WC, Recchia FA. 2010. Lipotoxicity and the development of heart failure: moving from mouse to man. Cell Metab 12:555-556.
72. Stec JJ, Silbershatz H, Tofer GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB Sr. 2000. Association of fbrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Ofspring Population. Circulation 102:1634-1638.
73. Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I, Baranowski M, Zendzian-Piotrowska M, Brzezinska Z, Gorski J. 2004. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53:1215-1221. (Pubitemid 38569006)
74. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. 2010. PPAR-induced cardiolipotoxicity in mice is ameliorated by PPARa defciency despite increases in fatty acid oxidation. J Clin Invest 120:3443-3454.
75. Sowers JR. 2007. Metabolic risk factors and renal disease. Kidney Int 71:719-720. (Pubitemid 46624014)
76. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB. 2000. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 279:H2124-H2132.
77. Summers SA. 2006. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45:42-72. (Pubitemid 43170804)
78. Tappia PS, Singal T. 2008. Phospholipid-mediated signaling and heart disease. Subcell Biochem 49:299-324.
79. Tatar M, Bartke A, Antebi A. 2003. The endocrine regulation of aging by insulin-like signals. Science 299:1346-1351. (Pubitemid 36254639)
80. Turinsky J, O'Sullivan DM, Bayly BP. 1990. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 265:16880-16885.
81. Unger RH. 2002. Lipotoxic diseases. Annu Rev Med 53:319-336. (Pubitemid 34177884)
82. Van Gaal LF, Mertens IL, De Block CE. 2006. Mechanisms linking obesity with cardiovascular disease. Nature 444:875-880. (Pubitemid 46028447)
83. Van Herpen NA, Schrauwen-Hinderling VB. 2008. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav 94:231-241. (Pubitemid 351615422)
84. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. 2005. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048-1056. (Pubitemid 40862092)
85. Vaziri ND, Norris K. 2011. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31:189-196.
86. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Müller F. 2003. Genetics: infuence of TOR kinase on lifespan in C. elegans. Nature 426:620. (Pubitemid 38009359)
87. Wang MC, Bohmann D, Jasper H. 2005. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 121:115-125.
88. Wu D, Ren Z, Pae M, Guo W, Cui X, Merrill AH, Meydani SN. 2007. Aging up-regulates expression of infammatory mediators in mouse adipose tissue. J Immunol 179:4829-4839.
89. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. 2003. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111:419-426. (Pubitemid 36182219)
90. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic efects. Nature 423:762-769. (Pubitemid 36735700)
91. Yki-Järvinen H. 2005. Fat in the liver and insulin resistance. Ann Med 37:347-356. (Pubitemid 41379841)
92. Zafran S, Frasch M. 2002. Early signals in cardiac development. Circ Res 91:457-469.
93. Zeidan YH, Hannun YA. 2007. Activation of acid sphingomyelinase by protein kinase Cdelta-mediated phosphorylation. J Biol Chem 282:11549-11561. (Pubitemid 47100781)
94. Zhang Y, Ren J. 2011. Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension 57:148-150.
95. Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, Lu TA, Benzer S, Kapahi P. 2009. 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 139:149-160.